NASDAQ:FBLG FibroBiologics (FBLG) Stock Price, News & Analysis $0.84 -0.01 (-1.03%) Closing price 07/15/2026 04:00 PM EasternExtended Trading$0.86 +0.02 (+1.92%) As of 07/15/2026 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About FibroBiologics Stock (NASDAQ:FBLG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get FibroBiologics alerts:Sign Up Key Stats Today's Range$0.84▼$0.8950-Day Range$0.73▼$1.2452-Week Range$0.73▼$14.68Volume26,679 shsAverage Volume155,544 shsMarket Capitalization$5.12 millionP/E RatioN/ADividend YieldN/APrice Target$74.00Consensus RatingHold Company Overview FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas. Read More FibroBiologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreFBLG MarketRank™: FibroBiologics scored higher than 52% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingFibroBiologics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.Upside PotentialFibroBiologics has a consensus price target of $74.00, representing about 8,680.3% upside from its current price of $0.84.Amount of Analyst CoverageFibroBiologics has only been the subject of 3 research reports in the past 90 days.Read more about FibroBiologics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for FibroBiologics are expected to decrease in the coming year, from ($4.01) to ($4.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of FibroBiologics is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of FibroBiologics is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFibroBiologics has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about FibroBiologics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.87% of the float of FibroBiologics has been sold short.Short Interest Ratio / Days to CoverFibroBiologics has a short interest ratio ("days to cover") of 0.52, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in FibroBiologics has recently decreased by 0.90%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFibroBiologics does not currently pay a dividend.Dividend GrowthFibroBiologics does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment0.88 News SentimentFibroBiologics has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for FibroBiologics this week, compared to 4 articles on an average week. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, FibroBiologics insiders have not sold or bought any company stock.Percentage Held by Insiders9.30% of the stock of FibroBiologics is held by insiders.Percentage Held by InstitutionsFibroBiologics has minimal institutional ownership at this time.Read more about FibroBiologics' insider trading history. Receive FBLG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FibroBiologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FBLG Stock News HeadlinesFibroBiologics (NASDAQ:FBLG) Shares Up 5.4% - Still a Buy?July 10, 2026 | americanbankingnews.comFibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of DirectorsJuly 9, 2026 | prnewswire.comYour money is changingPorter Stansberry - who warned readers about Fannie Mae in 2006, called gold in 2008, and predicted COVID-era inflation - believes the U.S. dollar is undergoing its most significant reset since 1974. In a new documentary, Stansberry connects the tariffs, the Greenland obsession, the $1.4 trillion UAE deal, and disputes with China to what he calls Trump's New Dollar - and explains specific steps investors should take before a critical meeting of world leaders this December. | Porter & Company (Ad)FibroBiologics, Inc.: FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical TrialJuly 7, 2026 | finanznachrichten.deFibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical TrialJuly 7, 2026 | prnewswire.comFibroBiologics Secures New Private Placement FinancingJuly 1, 2026 | theglobeandmail.comFibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceJune 30, 2026 | prnewswire.comFibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesJune 29, 2026 | prnewswire.comSee More Headlines FBLG Stock Analysis - Frequently Asked Questions How have FBLG shares performed this year? FibroBiologics' stock was trading at $4.4980 at the start of the year. Since then, FBLG shares have decreased by 81.3% and is now trading at $0.8428. How were FibroBiologics' earnings last quarter? FibroBiologics Inc. (NASDAQ:FBLG) announced its earnings results on Thursday, April, 30th. The company reported ($1.33) earnings per share for the quarter, topping analysts' consensus estimates of ($1.33) by $0.00. When did FibroBiologics' stock split? FibroBiologics's stock reverse split before market open on Monday, March 30th 2026.The 1-20 reverse split was announced on Wednesday, March 25th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 27th 2026. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did FibroBiologics IPO? FibroBiologics (FBLG) raised $38 million in an initial public offering (IPO) on Wednesday, January 31st 2024. The company issued 4,806,226 shares at $8.00 per share. How do I buy shares of FibroBiologics? Shares of FBLG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of FibroBiologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that FibroBiologics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Visa (V) and Netflix (NFLX). Company Calendar Last Earnings4/30/2026Today7/15/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FBLG Previous SymbolNASDAQ:FBLG CIK1958777 Webwww.fibrobiologics.com Phone281-671-5150FaxN/AEmployees10Year Founded2021Price Target and Rating Average Price Target for FibroBiologics$74.00 High Price Target$140.00 Low Price Target$8.00 Potential Upside/Downside+8,680.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($6.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.65 million Net MarginsN/A Pretax MarginN/A Return on Equity-767.07% Return on Assets-195.56% Debt Debt-to-Equity RatioN/A Current Ratio1.59 Quick Ratio1.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.85 per share Price / Book0.46Miscellaneous Outstanding Shares6,080,000Free Float5,515,000Market Cap$5.12 million OptionableN/A Beta1.14 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:FBLG) was last updated on 7/16/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredWhat will Nvidia do next?Wall Street spends millions on supercomputers and analyst teams to forecast stock prices. Now a new predictive...TradeSmith | SponsoredJeff Brown and Marc Chaikin's latest AI prediction explainedJeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...Brownstone Research | SponsoredBlackRock just moved $150 billion into this "new internet"BlackRock CEO Larry Fink's 2026 chairman's letter compared tokenization to the birth of the internet - and the...Awesomely, LLC | Sponsored17,556% on WHAT?17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | Sponsored$30M Could Unlock $500M in MetalA small exploration company is sitting on an estimated $500 million worth of antimony - a critical defense met...i2i Marketing Group, LLC | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredElon’s message for AmericaElon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroBiologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroBiologics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
